Glenn Hanna, MD

Medical Oncology

Glenn Hanna, MD

View full profile

Related Videos

ReACT 1.0 Study Presented by Glenn Hanna, MD. Video

ReACT 1.0 Study Presented by Glenn Hanna, MD.

Dr. Glenn Hanna presented phase 2 data suggesting that circulating HPV DNA could serve as a real-time biomarker to guide treatment intensity in HPV-positive oropharyngeal cancer.

ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD Video

ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD

Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.

Glenn Hanna, MD Shares Phase 2 Study of Nivolumab for High-Risk Oral Leukoplakia Video

Glenn Hanna, MD Shares Phase 2 Study of Nivolumab for High-Risk Oral Leukoplakia

37% of patients with high-risk oral leukoplakia treated with preventative immunotherapy had proliferative leukoplakia regression and demonstrated favorable overall cancer-free survival.